Is GANX or JSPR more profitable?

Gain Therapeutics' return on equity of -161.59% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Jasper Therapeutics N/A -884.17% -143.83%

Is JSPR or CNTB more profitable?

Connect Biopharma's return on equity of -165.41% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Connect Biopharma N/A -165.41% -121.58%

Does the media refer more to JSPR or CNTB?

In the previous week, Connect Biopharma had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 5 mentions for Connect Biopharma and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.02 beat Connect Biopharma's score of -0.42 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, JSPR or PMVP?

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.42 N/A

Is JSPR or PMVP more profitable?

PMV Pharmaceuticals' return on equity of -78.11% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% PMV Pharmaceuticals N/A -78.11% -70.13%

Which has stronger valuation & earnings, JSPR or KLRS?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is JSPR or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -884.17% -143.83% Kalaris Therapeutics N/A -71.71% -42.95%

Jasper Therapeutics (JSPR) Competitors

$0.59 +0.02 (+3.28%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 -0.02 (-2.80%)

As of 07:54 PM Eastern

Compare

JSPR vs. GANX, CNTB, PMVP, KLRS, and YARW

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Gain Therapeutics (GANX), Connect Biopharma (CNTB), PMV Pharmaceuticals (PMVP), Kalaris Therapeutics (KLRS), and Yarrow Bioscience (YARW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 1.00 beat Jasper Therapeutics' score of 0.02 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Positive
Jasper Therapeutics	Neutral

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 3.9% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gain Therapeutics' return on equity of -161.59% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Jasper Therapeutics	N/A	-884.17%	-143.83%

Gain Therapeutics currently has a consensus target price of $7.50, suggesting a potential upside of 307.61%. Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,152.70%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Gain Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than Jasper Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,605.95	-$20.16M	-$0.50	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

Summary

Gain Therapeutics beats Jasper Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to Connect Biopharma?

Jasper Therapeutics (NASDAQ:JSPR) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Jasper Therapeutics has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market.

Jasper Therapeutics currently has a consensus price target of $7.33, indicating a potential upside of 1,152.70%. Connect Biopharma has a consensus price target of $6.86, indicating a potential upside of 523.38%. Given Jasper Therapeutics' higher probable upside, research analysts clearly believe Jasper Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Connect Biopharma had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 5 mentions for Connect Biopharma and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.02 beat Connect Biopharma's score of -0.42 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Connect Biopharma has higher revenue and earnings than Jasper Therapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Connect Biopharma	$60K	1,154.45	-$55.48M	-$1.19	N/A

Connect Biopharma's return on equity of -165.41% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Connect Biopharma	N/A	-165.41%	-121.58%

Summary

Connect Biopharma beats Jasper Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Jasper Therapeutics compare to PMV Pharmaceuticals?

Jasper Therapeutics (NASDAQ:JSPR) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by company insiders. Comparatively, 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PMV Pharmaceuticals' return on equity of -78.11% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
PMV Pharmaceuticals	N/A	-78.11%	-70.13%

Jasper Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 1,152.70%. PMV Pharmaceuticals has a consensus target price of $4.33, indicating a potential upside of 224.59%. Given Jasper Therapeutics' higher probable upside, equities analysts plainly believe Jasper Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.42	N/A

Jasper Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.00 beat Jasper Therapeutics' score of 0.02 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
PMV Pharmaceuticals	Positive

Summary

PMV Pharmaceuticals beats Jasper Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Jasper Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 3 mentions for Jasper Therapeutics and 1 mentions for Kalaris Therapeutics. Jasper Therapeutics' average media sentiment score of 0.02 beat Kalaris Therapeutics' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Kalaris Therapeutics	Neutral

Jasper Therapeutics presently has a consensus target price of $7.33, suggesting a potential upside of 1,152.70%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 510.75%. Given Jasper Therapeutics' higher possible upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Kalaris Therapeutics' return on equity of -71.71% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Jasper Therapeutics and Kalaris Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Yarrow Bioscience?

Jasper Therapeutics (NASDAQ:JSPR) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Jasper Therapeutics has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Yarrow Bioscience's return on equity of -84.40% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Yarrow Bioscience has higher revenue and earnings than Jasper Therapeutics. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
Yarrow Bioscience	$570K	122.12	-$26.48M	-$14.64	N/A

Jasper Therapeutics has a beta of 3.04, suggesting that its share price is 204% more volatile than the broader market. Comparatively, Yarrow Bioscience has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market.

Jasper Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 1,152.70%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 122.48%. Given Jasper Therapeutics' higher possible upside, equities analysts clearly believe Jasper Therapeutics is more favorable than Yarrow Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Jasper Therapeutics had 1 more articles in the media than Yarrow Bioscience. MarketBeat recorded 3 mentions for Jasper Therapeutics and 2 mentions for Yarrow Bioscience. Jasper Therapeutics' average media sentiment score of 0.02 beat Yarrow Bioscience's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Jasper Therapeutics	Neutral
Yarrow Bioscience	Neutral

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Jasper Therapeutics beats Yarrow Bioscience on 8 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.73M	$3.92B	$7.26B	$13.10B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	14.07	274.98	25.77
Price / Sales	N/A	1,481.97	679.25	97.61
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.90	15.46	10.52	6.34
Net Income	-$75.80M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-7.68%	-2.21%	-1.08%	-0.11%
1 Month Performance	-18.96%	-6.66%	-3.39%	-3.42%
1 Year Performance	-74.88%	30.99%	15.08%	5.46%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	1.7045 of 5 stars	$0.59 +3.3%	$7.33 +1,152.7%	-76.4%	$20.73M	N/A	N/A	22	Gap Up High Trading Volume
GANX Gain Therapeutics	2.1061 of 5 stars	$1.85 +0.3%	$7.50 +306.5%	+5.1%	$80.52M	$50K	N/A	21
CNTB Connect Biopharma	3.1963 of 5 stars	$1.28 -3.4%	$7.29 +471.4%	-34.0%	$80.04M	$60K	N/A	64	Analyst Forecast Gap Down
PMVP PMV Pharmaceuticals	3.6053 of 5 stars	$1.48 +0.5%	$4.33 +192.2%	-0.7%	$77.41M	N/A	N/A	54	Positive News
KLRS Kalaris Therapeutics	2.8228 of 5 stars	$3.25 -0.2%	$18.75 +477.8%	-34.6%	$77.26M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. GANX, CNTB, PMVP, KLRS, and YARW

How does Jasper Therapeutics compare to Gain Therapeutics?

Summary

How does Jasper Therapeutics compare to Connect Biopharma?

Summary

How does Jasper Therapeutics compare to PMV Pharmaceuticals?

Summary

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Summary

How does Jasper Therapeutics compare to Yarrow Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. GANX, CNTB, PMVP, KLRS, and YARW

How does Jasper Therapeutics compare to Gain Therapeutics?

Does the media favor GANX or JSPR?

Do insiders & institutionals hold more shares of GANX or JSPR?

Is GANX or JSPR more profitable?

Do analysts prefer GANX or JSPR?

Which has more risk & volatility, GANX or JSPR?

Which has stronger valuation and earnings, GANX or JSPR?

Summary

How does Jasper Therapeutics compare to Connect Biopharma?

Which has more risk and volatility, JSPR or CNTB?

Do analysts recommend JSPR or CNTB?

Do insiders & institutionals have more ownership in JSPR or CNTB?

Does the media refer more to JSPR or CNTB?

Which has preferable earnings and valuation, JSPR or CNTB?

Is JSPR or CNTB more profitable?

Summary

How does Jasper Therapeutics compare to PMV Pharmaceuticals?

Do insiders and institutionals believe in JSPR or PMVP?

Is JSPR or PMVP more profitable?

Do analysts recommend JSPR or PMVP?

Which has stronger earnings and valuation, JSPR or PMVP?

Which has more risk & volatility, JSPR or PMVP?

Does the media favor JSPR or PMVP?

Summary

How does Jasper Therapeutics compare to Kalaris Therapeutics?

Which has more volatility & risk, JSPR or KLRS?

Does the media favor JSPR or KLRS?

Do analysts recommend JSPR or KLRS?

Which has stronger valuation & earnings, JSPR or KLRS?

Is JSPR or KLRS more profitable?

Do institutionals & insiders hold more shares of JSPR or KLRS?

Summary

How does Jasper Therapeutics compare to Yarrow Bioscience?

Is JSPR or YARW more profitable?

Which has better earnings and valuation, JSPR or YARW?

Which has more volatility & risk, JSPR or YARW?

Do analysts rate JSPR or YARW?

Does the media favor JSPR or YARW?

Do institutionals and insiders believe in JSPR or YARW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools